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INTRODUCTION
E
pidermal growth factor receptor (EGF-R), a member of large type I receptor family, is a 
membrane protein, which binds ligands, such as EGF or transforming growth factor-A
(TGF-A), with the extra cellular region, containing ligand binding domain. This binding 
leads to the formation of monodimers and heterodimers mostly with cErbB2 (HER2), 
activating intrinsic tyrosine kinase region of the receptor, which leads to the stimulation of 
signaling pathways, including the downstream kinases, and triggers the gene transcription, 
cell proliferation and survival. Various growth factor signal pathways were found to be 
interactive (1). The so called cross-talk between estrogen receptor (ER) and growth factor 
(GF) signaling pathways was described, which can promote the escape from the growth 
inhibition by hormonal treatment, and consecutive resistance to the treatment. Tamoxifen 
resistant cells may retain ER and remain sensitive to estrogen deprivation with either ovarian 
DEODWLRQRUDURPDWDVHLQKLELWRUV,QFUHDVHGFRPSRQHQWVRI(*)5+(5VLJQDOLQJ
SDWKZD\VVXFKDVRYHUVWLPXODWLRQZLWKOLJDQGVLQFUHDVHGUHFHSWRUH[SUHVVLRQDPSOLILFD-
tion, increased heterodimerization, or increased downstream pathway elements, were found 
in acquired and de novo tamoxifen resistant BC cells (4), and cell lines (5). Increased GF 
signaling may also reduce the ER expression (6), which may lead to the insensitivity to all 
endocrine manipulations (7). 
The expression of EGF-R in breast cancer is generally assumed to represent the unfavorable 
event during the process called “tumor progression”. On clinical material, its predictive role 
has been fairly well defined. Patients whose tumors expressed the EGF-R responded less 
frequently to endocrine treatment, as compared to those tumors that did not express it 
(8,9). In these studies, as well as in our own study (10), levels of EGF-R were significantly 
higher in non-responders, than in responders to endocrine treatment. Interestingly, we 
found that the EGF-R values mostly were overlapped between responders and non-respond-
HUVEXWGLGQHYHUH[FHHGIPROPJLQWKRVHWXPRUVWKDWKDGUHJUHVVHGRQHQGRFULQH
WKHUDS\/DWHULWZDVUHSRUWHGWKDWWKH(*)5DQGRU+(5H[SUHVVLQJWXPRUVVHHPHGWR
be less responsive to tamoxifen, but not to aromatase inhibitors (11), which suggested the 
role of EGF-R in clinical resistance to tamoxifen. 
EGF-R is also assumed as a marker of autocrine regulation of tumor growth. TGF-A is one 
of its ligands, which could be expressed by same tumor cells, forming the autocrine loop. 
It was found that co-expression of EGF-R and TGF-A in early BC had the most significant 
effect on Disease-free interval (DFI) and overall survival (OS), higher than nodal status 
(12).
In accordance with the EGF-R role in endocrine- (tamoxifen-) resistance and autocrine tumor 
growth regulation, it was expected that the prognosis would be much poorer in patients with 
EGF-R expressing tumors. However, early results on its prognostic role in breast cancer 
remained conflicting. Harris and co-workers (13) found that the EGF-R-expressing operable 
breast cancer patients had shorter DFI and OS. EGF-R-positive tumors progressed more rap-
idly than EGF-R-negative ones, under the primary endocrine treatment (8). This suggested 
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ABSTRACT
Background: The expression of epidermal growth factor receptor (EGF-R) in breast cancer (BC) is gen-
erally considered as an unfavorable event during tumor progression. Its predictive role has been fairly 
well defined: EGF-R expression predicts tamoxifen un-responsiveness. EGF-R role in autocrine growth 
regulation was confirmed. However, reported results on its prognostic role in BC patients were conflict-
ing. The prognostic role of EGF-R after 15 years of follow-up is analyzed in a group of 70 localized BC 
patients, presented at diagnosis in clinical stages I-III.
Methods: BC patients newly diagnosed from December 1990 until March 1991, treated in accordance to 
the National Protocol, were selected for EGF-R analysis. Steroid receptors and EGF-R were determined 
at diagnosis in same frozen tissue samples, using biochemical methods. Except 6 patients who were 
lost from follow-up in the interval shorter than 60 months, the remaining patients were followed-up from 
60-188 months. The total number of events was 32 relapses (46%), and 27 deaths (38.5%). 
Results: EGF-R expression was found in 28/70 patients (40%), and the EGF-R content higher than 
26 fmol - in 15/70 patients (21%). Neither the expression, nor the high content of EGF-R showed any 
infuence on disease-free or overall survival. Levels of EGF-R were similar in relapsing and relapse-free 
patients. Nodal status had the strongest influence on prognosis. 
Conclusion: Our results suggest that the controversial findings, regarding the EGF-R prognostic role, 
might be the consequence of a genuine weak influence of EGF-R expression on disease outcome.
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EGF-R prognostic role in breast cancer
that the EGF-R expression was a sign of more aggressive tumor behavior, or in other words, 
the unfavorable event. However, some authors found the prognostic value only in ER-nega-
tive (14-17), or only in node-negative operable breast carcinoma (15,16,18), while others 
did not find any prognostic significance of EGF-R (19-22). The reason for such controversial 
findings might be the use of too small patients’ groups, too short follow-up, retrospective 
analysis of the patients’ material, and the use of different methods for the EGF-R determina-
tion. On the contrary, the genuine weak influence of EGF-R expression on disease outcome 
could attribute to the inconsistency of the findings. Moreover, within studies that used the 
biochemical method for EGF-R determination, the lack of the commonly accepted cut-off 
value for EGF-R positivity could be the major cause of confusion. 
In 1996, in a sample of 106 unselected BC patients, we found that the EGF-R binding in indi-
YLGXDOEUHDVWFDUFLQRPDVZDVLQGHSHQGHQWRI(535FODVVLFSURJQRVWLFIDFWRUVQRGDOVWDWXV
tumor size and grade, age and menopausal status) and clinical stage of the disease. It has been 
concluded that the differences in EGF-R quantitative content represented the true biological dif-
ference between tumors (23). This was in contrast to other findings, but not all: some authors 
found the correlation between EGF-R expression and nodal status (24), or histology grade and 
even menopausal status (25), or age (26), but others mostly did not find such correlation.  In 
the analysis of OS in metastatic disease, we found a trend towards longer survival in patients 
whose EGF-R content was low, compared to those with the high EGF-R content (27). In the 
whole group of 106 unselected BC patients, when gradually increased the cut-off value by 5 
IPROPJIURPWRXSWRIPROPJWKHSURJQRVWLFVLJQLILFDQFHEHFDPHERUGHUOLQHDWWKH
OHYHORIIPROPJDQGVLJQLILFDQWDWWKHOHYHORIDQGHVSHFLDOO\IPROPJ7KHVH
published data referred to the group of patients unselected according to clinical stage and to the 
follow-up of 5-years. However, neither low nor high cut-off values of EGF-R had any significant 
prognostic influence in a subgroup of operable BC patients. Some more recently published 
studies with large number of patients showed significant influence of EGF-R on both DFI and 
OS (29,30), while others did not show any prognostic value of EGF-R (26).  
In the present paper, the prognostic role of EGF-R content is re-analyzed after 15 years of 
follow-up, in a subgroup of localized BC patients.
PATIENTS AND METHODS
Patients
Seventy patients with localized breast cancer have been included in present analysis, as the 
part of a larger sample of unselected consecutive breast cancer patients, newly diagnosed 
between December 1990 and March 1991 in the Institute of Oncology and Radiology of 
Serbia, Belgrade (27). 
The group consists of operable stage I-II BC patients (N=58), having been subjected to 
surgery as the primary treatment, and stage III patients (N=12), having been subjected to 
delayed radical mastectomy with axillary dissection, after primary (preoperative) radiother-
apy. They were presented at diagnosis as borderline operable, but became operable due to 
the response to radiotherapy. Details of patients’ characteristics are presented in Table 1. 
Patients were considered as premenopausal if they had regular menstrual cycles at the time 
of diagnosis; postmenopausal - if the last regular cycle occurred 5 or more years earlier; 
and perimenopause was defined as the interval between pre- and postmenopause.
Treatment
The choice of primary and consecutive treatment was done in accordance to the National 
%UHDVW&DQFHU3URWRFRO7KHSUHRSHUDWLYHDQGRUDGMXYDQWWUHDWPHQWGHSHQGHGRQFOLQLFDO
and pathological stage, tumor size, nodal involvement, histological grade, menstrual status 
and steroid receptor status: patients in early clinical stages (I-II) were routinely treated by 
surgery (modified radical mastectomy with axillary dissection in 53, and quadrantectomy 
without axillary dissection in 5 patients). Node-negative patients with histology grade I-II 
tumors were followed-up without any adjuvant treatment. The adjuvant treatment of high-risk 
node-negative (N-) patients, defined with tumor grade III, consisted of CMF chemotherapy 
(cyclophosphamide, methotrexate, 5-fluorouracil) in PR-negative (PR-), and endocrine 
therapy in PR-positive (PR+) patients (castration by irradiation in premenopausal, tamoxifen 
in postmenopausal). Node-positive (N+) operable breast cancer patients were treated with 
adjuvant CMF chemotherapy if they were PR-, and with CMF chemotherapy + endocrine 
therapy, if PR+. All postmenopausal N+ patients have been irradiated postoperatively. Those 
patients who were clinically classified at stage IIIa (T1-3, N2) and IIIb (T4b, N1-2) according 
to TNM classification, were subjected to biopsy only and irradiated preoperatively with tumor 
dose (TD) 45 Gy to the whole breast, and 45 Gy to regional lymphatics, in 15 fractions both, 
every second day during 6 weeks. Two months later (if responded), they were subjected to 
radical mastectomy with axillary dissection. All stage III patients, presented here, responded 
to radiotherapy. The further adjuvant treatment depended on pre-irradiation tumor status, 
postoperative patho-histological nodal status, as well as on histological tumor grade and 
receptor status of primary tumor, on the same way as in patients primarily operated. EGF-R 
findings were not known at the time of adjuvant treatment making decision.
Table 1. Patients’ and tumors’ characteristics
Characteristics No pts. %
Histologically confirmed invasive BC 70 100
Age
<45
45-59
>=60
17
35
18
24
50
26
Menopausal status
Premenopausal
Perimenopausal
Postmenopausal
31
8
31
44
11
44
Initial clinical stage
I
IIa
IIb
III
18
33
7
12
26
47
10
17
Tumor size 
pT1
pT2
pT3
T4b
36
26
3
5
52
37
4
7
Nodal status
0
1-3
>=4
unknown
32
12
8
18
46
17
11
26
Histology tumor type
IDC
ILC
Other
unknown
39
18
11
2
56
26
16
3
Histology tumor grade
I
II
III
unknown
8
51
10
1
11.5
73
14
1.5
Steroid receptors
ER+
PR+
(5DQGRU35
40
40
50
57
57
71
Abbreviations: IDC Invasive ductal carcinoma, ILC Invasive lobular carcinoma
The diagnosis of the first relapse has been routinely confirmed using X-ray, ultrasound, 
radionuclide and clinical examinations, as well as computed tomography (CT) and nuclear 
magnetic resonance (NMR) evaluation, when necessary.
The overall survival analysis was done after 15 years of follow-up. It was accepted that the 
breast cancer was the cause of death only in case when the patient had well documented 
progressive metastatic disease 1-3 months prior to death.
Receptor determination
Steroid receptors (SR) were determined at diagnosis, in tissue samples of breast cancer, using 
biochemical methods, which was previously described. An EGF-R content was determined in a 
membrane fraction of the same frozen tissue samples. Specific binding was calculated by subtract-
ing non-specific from total binding. Data were calculated according to Scatchard analysis (31-34).ZZZRQNQVDF\X$UFKLYH'HFHPEHU
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Statistics
In the analyses of parametric values, Chi-square and Fisher’s exact test were used. For 
comparison of the non-parametric values Man-Whitney-U test was used. Survival functions 
were presented by Kaplan-Meier method, and comparison of the groups was done by Log 
rank and Wilcoxon test. 
RESULTS
In a whole group, 5 and 6 patients were lost from follow-up in the interval shorter than 
60 months (median 54 and 55 months) for relapse and survival, respectively. Remaining 
patients were followed-up from 60 to 188 months (median 111.5 months for relapse and 
128 months for survival, respectively).
The total number of events was 32 relapses (46%), and 27 deaths (38.5%). Only one 
patient died in the 42
nd month of FU from the cause other than breast cancer. She died from 
the recurrent multiform glioblastoma, without signs of BC recurrence. Other deaths were 
caused by metastatic BC. 
(*)5YDOXHVYDULHGIURPPHGLDQIPROPJ$Q\PHDVXUDEOH(*)5H[SUHVVLRQ
!IPROPJZDVIRXQGLQSDWLHQWVDQGWKH(*)5FRQWHQWKLJKHUWKDQ
IPROPJLQSDWLHQWV7KHUHZDVQRFRUUHODWLRQZLWKHLWKHURWKHUSURJQRVWLF
factors, or age and menopausal status. However, the significant inverse relationship with 
both ER and PR was found.
We compared the DFS and OS in two groups of patients - those without the EGF-R expres-
sion in their tumors and the group with any measurable EGF-R expression (42 and 28 
patients, respectively). There was no difference either in DFS or in OS between groups 
)LJXUH:KHQWKHKLJKHUFXWRIIOHYHOZDVXVHGIPROPJDJDLQWKHUHZDVQR
difference either in the occurrence of relapse or survival (Figure 2). 
Figure 1. Disease-free interval (DFS) and Overall Survival (OS) in BC patients without the EGF-R 
H[SUHVVLRQ(*)5 DQGDQ\PHDVXUDEOH(*)5!IPROPJ
Figure 2. Disease-free interval (DFS) and overall survival (OS) in two subgroups of BC patients in 
UHJDUGWRWKH(*)5FRQWHQWXVLQJWKHFXWRIIYDOXHRIIPROPJ
No difference in the outcome between ER-positive vs. ER-negative patients was found, as well 
as between PR-positive vs. PR-negative (30 vs. 40 pts both, respectively) (not presented). 
Moreover, there was no difference in EGF-R content between patients who relapsed and 
those who remained disease-free (Figure 3). 
Figure 3. EGF-R content in relapsing and disease free patients
Among other prognostic parameters, nodal status (Figure 4) and clinical stage at diagnosis 
had the strongest influence on prognosis. All patients were divided by the involvement and 
WKHQXPEHURILQYROYHGQRGHVLQS1S1S1DQGWKRVHZLWKFOLQLFDO1FDWHJRU\DW
diagnosis. Interestingly, both relapse-free and overall survival were similar in node-negative 
patients and those with 1-3 nodes, and significantly better than in both groups with advanced 
QRGDOLQYROYHPHQW1DQGWKRVHZLWKFOLQLFDOO\1QRGDOVWDWXV6LPLODUUHVXOWZDVIRXQG
in regards to the clinical stage at diagnosis, concerning the DFI, but not the OS: Stage I and 
IIa patients had significantly better DFS, than stage IIb and III patients (not presented). 
1HåNRYLþ.RQVWDQWLQRYLþ=HWDOZZZRQNQVDF\X$UFKLYH'HFHPEHU
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Figure 4. Disease-free interval (DFS) and overall survival (OS) with respect to the nodal status (N) 
of BC patients
DISSCUSSION
Although the expression of growth factor receptors is commonly thought to be the unfavorable 
prognostic event, our results, published earlier, showed that a prognostic role of EGF-R expression 
in early breast cancer patients was negligible (27). This was in accordance with the other findings 
of a weak, if any, influence of EGF-R on the outcome of operable breast cancer (16,26). 
After the follow-up of 15 years, neither the expression, nor the higher cut-offs, when used in 
a group of operable breast cancer patients, did not change our previous results: there was no 
difference in the outcome between EGF-R negative and EGF-R positive localized BC patients. 
In addition, the EGF-R content, determined in relapsing patients, in comparison to those 
who were still relapse-free, showed no significant difference.
The inverse relationship between EGF-R and ER, often reported in clinical studies (35) was 
also confirmed in this study: ER+ tumors more frequently had no EGF-R, or its content 
was low, in comparison with ER- tumors, but the direct correlation of their levels was not 
confirmed, as reported earlier (23). The commonly used term “inverse” relationship obvi-
ously refers to the proportion of ER positive and EGF-R positive cells within a whole tumor. 
Therefore, it does not exclude the independence of their expression. 
,QRXUSUHYLRXVDQDO\VLVZHIRXQGWKDWSDWLHQWVZKRVH(*)5FRQWHQWZDVEHORZIPRO
mg, had significantly better prognosis than those with EGF-R content above this cut-off level 
(28). It seemed that the tumors with EGF-R content lower than this cut-off could be estrogen 
dependent (10). These results were obtained on the larger unselected BC patients` group, 
but in the group of operable BC patients, at the point of 5 years follow-up, there was only 
a non-significant trend towards the influence of EGF-R on outcome. Similar results were 
published by Foekens (36) and Klijn (37) who found, in operable breast cancer patients, that 
WKHJURXSZLWK´LQWHUPHGLDWHµFRQWHQWIPROPJKDGORZHUULVNRIUHFXUUHQFHWKDQ
ERWKJURXSVZLWKORZ(*)5FRQWHQWIPROPJDQGWKRVHZLWKKLJK(*)5FRQWHQW
The offered explanation for this phenomenon implies the possibility that tumors with low 
EGF-R content do not secrete TGF-A, they do not display autocrine-regulated growth, and 
consequently they may be endocrine-responsive. The alternative explanation suggested that 
receptors for EGF could be saturated and masked by their ligand (38). 
We have previously found that certain carcinomas were still endocrine regulated and endo-
crine sensitive as well, although contained EGF-R (10). Nicholson et al (39) found different 
levels of endocrine insensitivity between highly and moderately EGF-R-positive tumors, 
according to the level of immunostaining. Therefore, it could be concluded that the quantita-
tive EGF-R content is associated with the level of the loss of endocrine sensitivity. In addition, 
Nicholson et al (8,9) found the lower levels of EGF-R in responders, than in non-responders 
to endocrine therapy. In our study, all patients with endocrine responsive tumors received 
adjuvant tamoxifen or ovarian ablation: their outcome must be changed (improved) in regards 
with the “natural” course of disease. Thus, it seems noteworthy to analyze the prognostic 
value of EGF-R in the subgroup of patients who did not receive any adjuvant treatment.
2EYLRXVO\WKHH[SUHVVLRQRI(*)5ZKLFKLVUHODWHGWRWKHLQFUHDVHG(*)5+(5VLJQDOLQJ
leading to increased cell proliferation and survival, tamoxifen and probably endocrine insensi-
tivity and much aggressive tumor behavior – represents the unfavorable event. However, our 
results, presented here, show that the weak prognostic influence of EGF-R level disappeared 
after 15 years of FU. Similar loss of prognostic influence was confirmed by Klijn et al. (37).
It is unusual that expression of EGF-R does not influence directly the outcome of early BC 
patients. Controversial reports still appear (40). Even in studies that confirm the prognostic 
value of EGF-R (30), the real clinical usefulness of this finding is questionable. EGF-R prob-
ably is one of the most important factors in the complex orchestra of growth regulation and 
HQGRFULQHVHQVLWLYLW\UHVLVWDQFHPHFKDQLVPV7KXVWKHIXUWKHULQYHVWLJDWLRQRIFRH[SUHV-
sion and co-operation of EGF-R with other factors, such as HER2, TGF-A and others, could 
probably be of clinical interest, as well as the investigation of the role of elevated multiple 
elements of signaling pathways in BC prognosis (41). 
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